English Aron R.'s Form 4 filing
Anebulo Pharmaceuticals, Inc. (ANEB) · filed Dec 21, 2021
- Accession no.
- 0001493152-21-032220
- Filed
- Dec 21, 2021, 8:39 PM ET
- Trade date
- Dec 17, 2021
- Filing delay
- 4 days
- Rule 10b5-1 plan
- Not on the form (before 2023)
This filing lists 1 non-derivative transaction. Open-market purchases total $2.63K. It was filed 4 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| English Aron R.CIK 0001770436 | Director, 10% Owner, Other: See Explanation of Responses |
| 22NW Fund, LPCIK 0001640809 | Other: See Explanation of Responses |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Dec 17, 2021 | Common Stock, par value $0.001 per share | PPurchaseAcquired | +400 | $6.59F2 | +$2,634.32 | 3,362,713 | Indirect |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F2
This transaction was executed in multiple trades at prices ranging from $6.35 to $6.67. The price above reflects the weighted average sale price.
Referenced by the price of 1 transaction in Table I.